Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

RATIONALE & OBJECTIVE: The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of these agents. The literature on the nephrotoxicity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamlouk, Omar, Selamet, Umut, Machado, Shana, Abdelrahim, Maen, Glass, William F., Tchakarov, Amanda, Gaber, Lillian, Lahoti, Amit, Workeneh, Biruh, Chen, Sheldon, Lin, Jamie, Abdel-Wahab, Noha, Tayar, Jean, Lu, Huifang, Suarez-Almazor, Maria, Tannir, Nizar, Yee, Cassian, Diab, Adi, Abudayyeh, Ala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322290/
https://www.ncbi.nlm.nih.gov/pubmed/30612580
http://dx.doi.org/10.1186/s40425-018-0478-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322290/
https://www.ncbi.nlm.nih.gov/pubmed/30612580
http://dx.doi.org/10.1186/s40425-018-0478-8

Ejemplares similares